Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00290966
Other study ID # EFC6044
Secondary ID XRP6976E-325
Status Completed
Phase Phase 2/Phase 3
First received February 9, 2006
Last updated April 28, 2009
Start date October 1998
Est. completion date May 2003

Study information

Verified date April 2009
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationEuropean Union: European Medicines Agency
Study type Interventional

Clinical Trial Summary

Phase II:

Primary objective: to select one of the 2 test arms (docetaxel with cisplatin, docetaxel with cisplatin and 5-FU), based primarily on complete responses, to advance to a phase III survival comparison against the CDDP + 5-FU control arm.

Secondary objective: to evaluate the quantitative and qualitative safety profile of the 2 test groups.

Phase III:

Primary objective: to detect a statistically significant increase in time to progression (TTP) for the test arm (docetaxel plus cisplatin and 5-FU) relative to the control arm (cisplatin plus 5-FU).

Main secondary objective: to detect a statistically significant increase in overall survival (OS) for the test arm (docetaxel plus cisplatin and 5-FU) relative to the control arm (cisplatin plus 5-FU).

Other secondary objectives: to compare response rates, time to treatment failure, duration of response, safety profiles, quality of life and disease-related symptoms.Socio-economic data will be collected in order to be able to perform an analysis by country when necessary.


Recruitment information / eligibility

Status Completed
Enrollment 610
Est. completion date May 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patient's consent form obtained, signed and dated before beginning specific protocol procedures.

- Gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction, histologically proven.

- Measurable and/or evaluable metastatic disease; if a single metastatic lesion is the only manifestation of the disease, cytology or histology is mandatory. Locally recurrent disease is accepted provided that there is at least one measurable lesion (e.g. lymph node).

- Performance status Karnofsky index > 70%.

- Life expectancy of more than 3 months.

- Adequate haematological and biochemistry parameters

- No prior palliative chemotherapy, previous adjuvant (and/or neo-adjuvant) chemotherapy is allowed if more than 12 months has elapsed between the end of adjuvant (or neo-adjuvant) therapy and first relapse.

Exclusion Criteria:

- Pregnant or lactating women.

- Patients (M/F) with reproductive potential not implementing adequate contraceptive measures.

- Other tumor type than adenocarcinoma (leiomyosarcoma ; lymphoma).

- Any prior palliative chemotherapy. Prior adjuvant (and/or neo-adjuvant) chemotherapy with a first relapse within 12 months from the end of adjuvant (or neo-adjuvant).

- Prior treatment with taxanes. Prior CDDP as adjuvant (and/or neo-adjuvant) chemotherapy with cumulative dose > 300 mg/m².

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
XRP6976


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

References & Publications (1)

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression
Secondary Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months.
See also
  Status Clinical Trial Phase
Completed NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT05645198 - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy Phase 4
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Not yet recruiting NCT06085677 - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Recruiting NCT02969122 - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor N/A
Completed NCT01482299 - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression Phase 2
Active, not recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Completed NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Completed NCT03071237 - The Origin of Infrapyloric Artery
Recruiting NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Phase 2
Completed NCT05714878 - Multimodal Prehabilitation for Resectable Gastric Cancer N/A
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05640609 - Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer Phase 1/Phase 2